Progen Pharmaceuticals: Clinical Trials

7 trials sponsored by Progen Pharmaceuticals, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 terminated. 4 Phase 1, 2 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 14Completed 4
Phase 22Completed 1, Terminated 1
Phase 31Terminated 1

Follow Progen Pharmaceuticals: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma
PI-88, placebo - Cancer, Liver Cancer
Phase 3TerminatedProgen Pharmaceuticals6002007-12-012011-06-15
Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD
CGC-11047 - Age Related Macular Degeneration
Phase 1CompletedProgen Pharmaceuticals432007-04-012012-08-06
Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer
CGC-11047 - Prostate Cancer
Phase 2TerminatedUniversity of Wisconsin, Madison232006-06-012015-10-02
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
CGC-11047 and gemcitabine, CGC-11047 and docetaxel, CGC-11047 and bevacizumab - Cancer
Phase 1CompletedProgen Pharmaceuticals1722006-05-012016-07-21
SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma
polyamine analogue PG11047 - Lymphoma
Phase 1CompletedProgen Pharmaceuticals202006-01-012016-06-23
Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer
PI-88, docetaxel, prednisone - Prostate Cancer
Phase 2CompletedProgen Pharmaceuticals482005-08-012011-06-15
Study of CGC-11047 (PG-11047) in Subjects With Advanced Refractory Solid Tumors
PG-11047 - Cancer
Phase 1CompletedProgen Pharmaceuticals462005-03-012012-03-27

Conditions studied

Neoplasms (3)  ·  Lymphoma (2)  ·  Prostatic Neoplasms (2)  ·  Burkitt Lymphoma (1)  ·  Carcinoma, Hepatocellular (1)  ·  Hodgkin Disease (1)  ·  Immunoblastic Lymphadenopathy (1)  ·  Liver Neoplasms (1)  ·  Lymphoma, B-Cell, Marginal Zone (1)  ·  Lymphoma, Follicular (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Lymphoma, Large-Cell, Anaplastic (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Lymphoma, T-Cell, Cutaneous (1)  ·  Macular Degeneration (1)

Interventions

(N(1),N(12))bis(ethyl)-6,7-dehydrospermine (3)  ·  CGC 11047 (3)  ·  Docetaxel (2)  ·  phosphomannopentaose sulfate (2)  ·  Bevacizumab (1)  ·  Cisplatin (1)  ·  Erlotinib Hydrochloride (1)  ·  Fluorouracil (1)  ·  Gemcitabine (1)  ·  Leucovorin (1)  ·  Prednisone (1)  ·  Sunitinib (1)

Countries

United States (6)  ·  Australia (2)  ·  Canada (1)  ·  Hong Kong (1)  ·  Italy (1)  ·  Malaysia (1)  ·  Mexico (1)  ·  Russia (1)  ·  Singapore (1)  ·  Spain (1)  ·  Taiwan (1)  ·  Thailand (1)

Top investigators

Barbara Hicks (1)  ·  Gavin Marx, MD (1)  ·  Joe Stephenson, MD (1)  ·  Mark Ratain, M.D. (1)  ·  Nick Pavlakis, MD (1)  ·  Peter Campochiaro, MD (1)  ·  Ronnie TP Poon, MD (1)

Results publications

PMID 32447421